Adavosertib Induces Tumor Shrinkage in 30% of Patients with Uterine Serous Carcinoma

A recent clinical trial ’s results found that a targeted drug known as adavosertib caused tumors in nearly 30% of patients examined with uterine serous carcinoma, a hard-to-treat form of uterine cancer.

Source: CancerNetwork - April 29, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news